TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00631800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pagibaximab (formerly BSYX-A110)
Description: Pagibaximab at 60, 90 mg/kg intravenously at Days 0, 7, 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pagibaximab (formerly BSYX-A110)
Description: Pagibaximab at 60, 90 mg/kg intravenously at Days 0, 7, 14

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pagibaximab (formerly BSYX-A110)
Description: Pagibaximab at 60, 90 mg/kg intravenously at Days 0, 7, 14
Study: NCT02598622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcarnitine
Description: Acetylcarnitine is taken 2 times a day for days 1 through 21.
Study: NCT03264872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Enhanced Motivational Interviewing
Description: Target clients in this Peer-Enhanced Motivational Interviewing arm will receive separate one-hour Motivational Interviewing (MI) sessions, in which the therapist reviews the target clients substance use behaviors in a non-confrontational manner, listens empathetically, and reinforces any client statements indicating a desire the change. In this arm, the therapist also presents the target client's peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication sills they can use to influence the target client's substance use behaviors.

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Control
Description: After the 12 week follow up period, if subjects in the Waitlist Control group desire to receive the Peer-Enhanced Motivational Interviewing intervention, that will be made available to them.
Study: NCT00935025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: single and multiple oral doses, extended-release capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single and multiple oral doses, capsule
Study: NCT04529213

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion Treatment
Description: The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion Treatment
Description: The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion Treatment
Description: The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.
Study: NCT06299501

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine questions
Description: The routine group of nurses receive training and supervision and will ask questions about family violence to everyone, disregarding if they suspect family violence or not.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Questions on evidence based indication
Description: The group of nurses will receive training and supervision and will ask questions on evidence based indication

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: The group of nurses will ask questions when suspecting ongoing violence in the family
Study: NCT01820676

Intervention type: DEVICE
Intervention: iUni G2+
Description: The iUni G2+ Unicompartmental Resurfacing Device (iUni) is an FDA cleared and CE Marked implant designed for patients with damage isolated to either the medial or lateral tibiofemoral compartment of the knee. The patient-specific iUni is designed from a CT scan of an individual patient's knee using a design process which interactively maps the diseased area and defines the extent of misalignment present in the knee. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation (Fitz).
Study: NCT02709954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active inhaled delta-9-THC
Description: Low dose THC (\~4 mg), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes via a vaporizer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active inhaled delta-9-THC
Description: Low dose THC (\~4 mg), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes via a vaporizer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Control: Approximately 4 drinks of orange juice or ginger ale covered by a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
Study: NCT00059930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study: NCT03108222

Intervention type: OTHER
Intervention: Phosphorus Absorption Test
Description: Subjects will undergo a radiophosphorus (P-33) absorption test over two days, that will include an oral administration of P-33 on the 1st day of the test, and an IV administration of P-33 on the 2nd day of the test. P-33 activity from serial serum and urine collections will be determined by scintillation counting, and fractional phosphorus absorption calculated by kinetic modeling.

Intervention type: OTHER
Intervention: Phosphorus Absorption Test
Description: Subjects will undergo a radiophosphorus (P-33) absorption test over two days, that will include an oral administration of P-33 on the 1st day of the test, and an IV administration of P-33 on the 2nd day of the test. P-33 activity from serial serum and urine collections will be determined by scintillation counting, and fractional phosphorus absorption calculated by kinetic modeling.
Study: NCT01243086

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ranibizumab
Description: Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
Study: NCT00059930

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study: NCT01368601

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP (Continuous airway pressure)
Description: To evaluate if continuous positive airway pressure (CPAP) on the lung undergoing lobectomy can decrease the inflammatory response and PPC.
Study: NCT03922308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive injection of placebo matched to SHP655.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive injection of placebo matched to SHP655.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP655
Description: Participants will receive injection of SHP655.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP655
Description: Participants will receive injection of SHP655.
Study: NCT01243086

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OZURDEX
Description: OZURDEX injection of 0.7mg dosage at months 0 with follow up for a total of 6 months.
Study: NCT02598622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is taken 2 times a day for days 1 through 21.
Study: NCT01093976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: 2.5mg-15mg by mouth once a day for twelve-weeks
Study: NCT05786053

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: graded recession of inferior oblique muscle
Description: . Graded recession of IO muscle depends on the amplitude of the V-pattern and degree of IOOA. Eight mm recession for amplitude 7.5 to 10 degree and mild IOOA (10 degree or +1) ,10 mm recession for amplitude 11- 15 degree and moderate IOOA (11 -15 or +2) and maximum recession for amplitude more than 15 degree and marked IOOA (more than15 degree or +3). Simultaneous correction of the horizontal deviation was performed at the same sitting.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: graded recession of inferior oblique muscle
Description: . Graded recession of IO muscle depends on the amplitude of the V-pattern and degree of IOOA. Eight mm recession for amplitude 7.5 to 10 degree and mild IOOA (10 degree or +1) ,10 mm recession for amplitude 11- 15 degree and moderate IOOA (11 -15 or +2) and maximum recession for amplitude more than 15 degree and marked IOOA (more than15 degree or +3). Simultaneous correction of the horizontal deviation was performed at the same sitting.
Study: NCT03296553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: The experimental group will receive Valganciclovir 900 mg twice in a day before the initiation of cART until viral load of HHV-8 is undetectable.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral Combinations
Description: Patients will receive standard antiretroviral treatment as recommended
Study: NCT01946282

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIT Invitation Only
Description: Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIT plus $5 Incentive
Description: Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls. Patients are offered a small incentive to complete their screening.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIT plus $10 Incentive
Description: Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls. Patients are offered a small incentive to complete their screening.
Study: NCT01913873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: serum concentration changes cardiac biomarkers
Description: Serum concentration determination for cardiac biomarkers (CK-MB and Hs-cTn) preoperatively, at induction of anesthesia (after placement of the arterial line), upon arrival at the intensive care unit (ICU), as well as every 3 hours for 12 hours, then every 6 hours the following 12 hours and a last sample is taken 48 hours after surgery.
Study: NCT00701935

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection, twice a day
Study: NCT03922308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participants will receive PEX as Standard of Care (SOC).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participants will receive PEX as Standard of Care (SOC).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Participants will receive PEX as Standard of Care (SOC).
Study: NCT04958213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose prolotherapy injection
Description: 15% dextrose prolotherapy injection into the knee and 15% dextrose prolotherapy injection will be applied to the painful adhesions of the ligaments around the knee.
Study: NCT01812707

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alirocumab
Description: Two SC injections in the abdomen only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Two SC injections in the abdomen only
Study: NCT04958213

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: conventional physical therapy
Description: 4 weeks (20 sessions) physical therapy (Hotpack, TENS and Ultrasound) and home exercise program (isometric and isotonic exercises).
Study: NCT03662087

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: HMA+DLI
Description: HMA: Decitabine was administered at 20mg/m2/day for five consecutive days or Ara-C was administered at 75mg/m2/day for seven consecutive days. DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10\*8 mononuclear cells/kg.
Study: NCT01812707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Two SC injections in the abdomen only

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for alirocumab)
Description: Two subcutaneous (SC) injections in the abdomen only~Route of administration: subcutaneous injection (1 mL) in the abdomen
Study: NCT00701935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, twice a day, 10mcg
Study: NCT03457337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 plus Gefitinib
Description: S-1: According to the body surface area (BSA) to determine the dose, twice daily, after breakfast and dinner orally Gefitinib: 250mg, 1 day, orally, fasting or with the same service

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: Gefitinib: 250mg, 1 day, orally
Study: NCT03662087

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DLI
Description: DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10\*8 mononuclear cells/kg.
Study: NCT04664569

Intervention type: OTHER
Intervention: observational study
Description: observational study
Study: NCT00569231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candida Antigen
Description: Intralesional injection of 0.3ml candida antigen into largest wart at baseline visit and then every 3 weeks +/- 3 days for a maximum of 10 treatments.
Study: NCT00683332

Intervention type: DRUG
Intervention: Tigecycline (Tygacil)
Description: This is a non-interventional study; patients are administered Tygacil as prescribed by their doctor as per registered indications stated in product label/insert (50 mg by Intravenous Injection).
Study: NCT03722537

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteochondral Allograft
Description: The arthritic bone that the thumb rests on (the trapezium) is removed and replaced with femoral trochlear osteochondral allograft that is designed to be similar in morphology to the human trapezium articular surface.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ligament Reconstruction Tendon Interposition
Description: During the LRTI, the arthritic bone that the thumb rests on (the trapezium) is removed. A small cut is made in the forearm to release a tendon, which is moved to the base of the thumb to fill in the area from which the trapezium bone was removed. A small suture anchor is then placed into a thumb bone which holds everything together.
Study: NCT02962648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside/ferric derisomaltose
Description: Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride from the site's supply and administered over approximately 20 minutes using IV infusion.
Study: NCT03970629

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PERSONA Total Knee
Description: Primary Total Knee Arthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PERSONA Total Knee
Description: Primary Total Knee Arthroplasty
Study: NCT01394731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Study: NCT02897453

Intervention type: DEVICE
Intervention: The Spinal Tethering System
Description: An implant comprised of: vertebral body screws, vertebral body staples (washers), and a PET (polyethylene-terephthalate) cord.
Study: NCT04477083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhalable hydroxychloroquine (HCQ)
Description: inhalable hydroxychloroquine (HCQ) plus supportive and symptomatic treatment
Study: NCT01394731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine
Study: NCT02709954

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: Approximately 4 drinks of orange juice or ginger ale covered by a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
Study: NCT04477083

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: supportive and symptomatic treatment
Description: supportive and symptomatic treatment
Study: NCT02709954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Control: No active THC. Administered over 20 minutes via a vaporizer. approximately 10 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: No active THC. Administered over 20 minutes via a vaporizer. approximately 10 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Oral Ethanol
Description: 0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to consuming approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.
Study: NCT04134533

Intervention type: OTHER
Intervention: Gross Motor Function Measurement
Description: These instruments will be used for determine the gross motor functional level and quality of life of the children with cerebral palsy and anxiety, depression levels of caregivers.
Study: NCT02230085

Intervention type: OTHER
Intervention: Administration of the questionnaire and monitoring of CPAP adherence
Study: NCT02450760

Intervention type: OTHER
Group type: OTHER
Intervention: Social incentive
Description: Quantify adherence to 90 days of home blood pressure monitoring and to determine if a social incentive improves adherence

Intervention type: OTHER
Group type: OTHER
Intervention: Social incentive
Description: Quantify adherence to 90 days of home blood pressure monitoring and to determine if a social incentive improves adherence
Study: NCT04400383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB011 Injection
Description: Stage 1 Single treatment: AB011 Injection with dose escalation of 1mg/kg up to 40mg/kg, as well as dose expansion with recommended dose level from dose escalation.~Stage 2 Combo Treatment: AB011 combine XELOX( GC) or Gem/nab-P (PC) Injection with dose escalation of 10mg/kg up to 30mg/kg, as well as dose expansion with recommended dose level from dose escalation.
Study: NCT03238664

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy of bladder tumor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Intensity Focused Ultrasound Ablation
Description: Undergo laparoscopic HIFU
Study: NCT02709954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Oral Ethanol
Description: 0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to consuming approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.
Study: NCT04230473

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: single dose of CNCT19
Description: Dose A: 0.25 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose B: 1.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose C: 2.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide
Study: NCT01265329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Negative selection
Description: Sperm selection to continue the treatment with healthy sperm
Study: NCT03926507

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluciclovine F18
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan